nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2C9—Sorafenib—thyroid cancer	0.0408	0.405	CbGbCtD
Flecainide—CYP2D6—Sorafenib—thyroid cancer	0.0374	0.37	CbGbCtD
Flecainide—CYP2D6—Doxorubicin—thyroid cancer	0.0227	0.225	CbGbCtD
Flecainide—Flushing—Sorafenib—thyroid cancer	0.00404	0.00449	CcSEcCtD
Flecainide—Dyspepsia—Vandetanib—thyroid cancer	0.00403	0.00449	CcSEcCtD
Flecainide—Decreased appetite—Vandetanib—thyroid cancer	0.00398	0.00443	CcSEcCtD
Flecainide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00396	0.0044	CcSEcCtD
Flecainide—Ageusia—Epirubicin—thyroid cancer	0.00395	0.0044	CcSEcCtD
Flecainide—Fatigue—Vandetanib—thyroid cancer	0.00395	0.00439	CcSEcCtD
Flecainide—Immune system disorder—Sorafenib—thyroid cancer	0.00393	0.00437	CcSEcCtD
Flecainide—Pain—Vandetanib—thyroid cancer	0.00392	0.00436	CcSEcCtD
Flecainide—Constipation—Vandetanib—thyroid cancer	0.00392	0.00436	CcSEcCtD
Flecainide—Scotoma—Doxorubicin—thyroid cancer	0.0039	0.00434	CcSEcCtD
Flecainide—Dysphonia—Epirubicin—thyroid cancer	0.00389	0.00433	CcSEcCtD
Flecainide—Alopecia—Sorafenib—thyroid cancer	0.00385	0.00428	CcSEcCtD
Flecainide—Blood disorder—Epirubicin—thyroid cancer	0.00383	0.00426	CcSEcCtD
Flecainide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00375	0.00417	CcSEcCtD
Flecainide—Dysgeusia—Sorafenib—thyroid cancer	0.00371	0.00413	CcSEcCtD
Flecainide—Ageusia—Doxorubicin—thyroid cancer	0.00366	0.00407	CcSEcCtD
Flecainide—Abdominal pain—Vandetanib—thyroid cancer	0.00362	0.00403	CcSEcCtD
Flecainide—Body temperature increased—Vandetanib—thyroid cancer	0.00362	0.00403	CcSEcCtD
Flecainide—Dysphonia—Doxorubicin—thyroid cancer	0.0036	0.00401	CcSEcCtD
Flecainide—Blood disorder—Doxorubicin—thyroid cancer	0.00355	0.00395	CcSEcCtD
Flecainide—Skin discolouration—Epirubicin—thyroid cancer	0.00355	0.00394	CcSEcCtD
Flecainide—Dyskinesia—Epirubicin—thyroid cancer	0.00341	0.00379	CcSEcCtD
Flecainide—Syncope—Sorafenib—thyroid cancer	0.0034	0.00378	CcSEcCtD
Flecainide—Leukopenia—Sorafenib—thyroid cancer	0.00339	0.00377	CcSEcCtD
Flecainide—Loss of consciousness—Sorafenib—thyroid cancer	0.00333	0.0037	CcSEcCtD
Flecainide—Cough—Sorafenib—thyroid cancer	0.00331	0.00368	CcSEcCtD
Flecainide—Atrioventricular block—Epirubicin—thyroid cancer	0.0033	0.00367	CcSEcCtD
Flecainide—Asthenia—Vandetanib—thyroid cancer	0.00329	0.00366	CcSEcCtD
Flecainide—Skin discolouration—Doxorubicin—thyroid cancer	0.00328	0.00365	CcSEcCtD
Flecainide—Hypertension—Sorafenib—thyroid cancer	0.00327	0.00364	CcSEcCtD
Flecainide—Pruritus—Vandetanib—thyroid cancer	0.00324	0.00361	CcSEcCtD
Flecainide—Myalgia—Sorafenib—thyroid cancer	0.00323	0.00359	CcSEcCtD
Flecainide—Arthralgia—Sorafenib—thyroid cancer	0.00323	0.00359	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0032	0.00356	CcSEcCtD
Flecainide—Ventricular tachycardia—Epirubicin—thyroid cancer	0.0032	0.00356	CcSEcCtD
Flecainide—Abnormal dreams—Epirubicin—thyroid cancer	0.00317	0.00352	CcSEcCtD
Flecainide—Dry mouth—Sorafenib—thyroid cancer	0.00315	0.00351	CcSEcCtD
Flecainide—Dyskinesia—Doxorubicin—thyroid cancer	0.00315	0.00351	CcSEcCtD
Flecainide—Diarrhoea—Vandetanib—thyroid cancer	0.00314	0.00349	CcSEcCtD
Flecainide—Atrioventricular block—Doxorubicin—thyroid cancer	0.00306	0.0034	CcSEcCtD
Flecainide—Shock—Sorafenib—thyroid cancer	0.00304	0.00338	CcSEcCtD
Flecainide—Nervous system disorder—Sorafenib—thyroid cancer	0.00303	0.00337	CcSEcCtD
Flecainide—Dizziness—Vandetanib—thyroid cancer	0.00303	0.00337	CcSEcCtD
Flecainide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00303	0.00337	CcSEcCtD
Flecainide—Neuropathy—Epirubicin—thyroid cancer	0.00301	0.00334	CcSEcCtD
Flecainide—Skin disorder—Sorafenib—thyroid cancer	0.003	0.00334	CcSEcCtD
Flecainide—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00296	0.0033	CcSEcCtD
Flecainide—Anorexia—Sorafenib—thyroid cancer	0.00295	0.00328	CcSEcCtD
Flecainide—Abnormal dreams—Doxorubicin—thyroid cancer	0.00293	0.00326	CcSEcCtD
Flecainide—Coma—Epirubicin—thyroid cancer	0.00293	0.00325	CcSEcCtD
Flecainide—Vomiting—Vandetanib—thyroid cancer	0.00291	0.00324	CcSEcCtD
Flecainide—Rash—Vandetanib—thyroid cancer	0.00289	0.00321	CcSEcCtD
Flecainide—Dermatitis—Vandetanib—thyroid cancer	0.00289	0.00321	CcSEcCtD
Flecainide—Headache—Vandetanib—thyroid cancer	0.00287	0.00319	CcSEcCtD
Flecainide—Pulmonary oedema—Epirubicin—thyroid cancer	0.00285	0.00317	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00282	0.00313	CcSEcCtD
Flecainide—Neuropathy—Doxorubicin—thyroid cancer	0.00278	0.00309	CcSEcCtD
Flecainide—Dyspnoea—Sorafenib—thyroid cancer	0.00276	0.00307	CcSEcCtD
Flecainide—Nausea—Vandetanib—thyroid cancer	0.00272	0.00303	CcSEcCtD
Flecainide—Dyspepsia—Sorafenib—thyroid cancer	0.00272	0.00303	CcSEcCtD
Flecainide—Coma—Doxorubicin—thyroid cancer	0.00271	0.00301	CcSEcCtD
Flecainide—Decreased appetite—Sorafenib—thyroid cancer	0.00269	0.00299	CcSEcCtD
Flecainide—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00267	0.00297	CcSEcCtD
Flecainide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00267	0.00297	CcSEcCtD
Flecainide—Fatigue—Sorafenib—thyroid cancer	0.00267	0.00296	CcSEcCtD
Flecainide—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00266	0.00296	CcSEcCtD
Flecainide—Pain—Sorafenib—thyroid cancer	0.00264	0.00294	CcSEcCtD
Flecainide—Constipation—Sorafenib—thyroid cancer	0.00264	0.00294	CcSEcCtD
Flecainide—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00264	0.00293	CcSEcCtD
Flecainide—Hepatic failure—Epirubicin—thyroid cancer	0.00259	0.00288	CcSEcCtD
Flecainide—Eye pain—Epirubicin—thyroid cancer	0.00258	0.00286	CcSEcCtD
Flecainide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00256	0.00285	CcSEcCtD
Flecainide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00253	0.00281	CcSEcCtD
Flecainide—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00247	0.00275	CcSEcCtD
Flecainide—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00246	0.00274	CcSEcCtD
Flecainide—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00246	0.00274	CcSEcCtD
Flecainide—Urticaria—Sorafenib—thyroid cancer	0.00246	0.00273	CcSEcCtD
Flecainide—Abdominal pain—Sorafenib—thyroid cancer	0.00244	0.00272	CcSEcCtD
Flecainide—Body temperature increased—Sorafenib—thyroid cancer	0.00244	0.00272	CcSEcCtD
Flecainide—Hepatic failure—Doxorubicin—thyroid cancer	0.00239	0.00266	CcSEcCtD
Flecainide—Eye pain—Doxorubicin—thyroid cancer	0.00238	0.00265	CcSEcCtD
Flecainide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00237	0.00264	CcSEcCtD
Flecainide—Diplopia—Epirubicin—thyroid cancer	0.00232	0.00259	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00232	0.00259	CcSEcCtD
Flecainide—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00228	0.00254	CcSEcCtD
Flecainide—Asthenia—Sorafenib—thyroid cancer	0.00222	0.00247	CcSEcCtD
Flecainide—Cardiac arrest—Epirubicin—thyroid cancer	0.00221	0.00246	CcSEcCtD
Flecainide—Pruritus—Sorafenib—thyroid cancer	0.00219	0.00243	CcSEcCtD
Flecainide—Ataxia—Epirubicin—thyroid cancer	0.00219	0.00243	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00215	0.00239	CcSEcCtD
Flecainide—Diplopia—Doxorubicin—thyroid cancer	0.00215	0.00239	CcSEcCtD
Flecainide—Diarrhoea—Sorafenib—thyroid cancer	0.00212	0.00235	CcSEcCtD
Flecainide—Cardiac arrest—Doxorubicin—thyroid cancer	0.00205	0.00227	CcSEcCtD
Flecainide—Dizziness—Sorafenib—thyroid cancer	0.00204	0.00227	CcSEcCtD
Flecainide—Ataxia—Doxorubicin—thyroid cancer	0.00202	0.00225	CcSEcCtD
Flecainide—Vomiting—Sorafenib—thyroid cancer	0.00197	0.00219	CcSEcCtD
Flecainide—Angina pectoris—Epirubicin—thyroid cancer	0.00196	0.00218	CcSEcCtD
Flecainide—Rash—Sorafenib—thyroid cancer	0.00195	0.00217	CcSEcCtD
Flecainide—Dermatitis—Sorafenib—thyroid cancer	0.00195	0.00217	CcSEcCtD
Flecainide—Headache—Sorafenib—thyroid cancer	0.00194	0.00215	CcSEcCtD
Flecainide—Dysuria—Epirubicin—thyroid cancer	0.00188	0.00209	CcSEcCtD
Flecainide—Nausea—Sorafenib—thyroid cancer	0.00184	0.00204	CcSEcCtD
Flecainide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00183	0.00204	CcSEcCtD
Flecainide—Hyperglycaemia—Epirubicin—thyroid cancer	0.00181	0.00202	CcSEcCtD
Flecainide—Angina pectoris—Doxorubicin—thyroid cancer	0.00181	0.00201	CcSEcCtD
Flecainide—Pneumonia—Epirubicin—thyroid cancer	0.0018	0.002	CcSEcCtD
Flecainide—Renal failure—Epirubicin—thyroid cancer	0.00176	0.00196	CcSEcCtD
Flecainide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00176	0.00195	CcSEcCtD
Flecainide—Jaundice—Epirubicin—thyroid cancer	0.00175	0.00194	CcSEcCtD
Flecainide—Dysuria—Doxorubicin—thyroid cancer	0.00174	0.00193	CcSEcCtD
Flecainide—Haematuria—Epirubicin—thyroid cancer	0.00171	0.0019	CcSEcCtD
Flecainide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.0017	0.00189	CcSEcCtD
Flecainide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00168	0.00187	CcSEcCtD
Flecainide—Agranulocytosis—Epirubicin—thyroid cancer	0.00167	0.00186	CcSEcCtD
Flecainide—Pneumonia—Doxorubicin—thyroid cancer	0.00167	0.00185	CcSEcCtD
Flecainide—Bradycardia—Epirubicin—thyroid cancer	0.00164	0.00182	CcSEcCtD
Flecainide—Renal failure—Doxorubicin—thyroid cancer	0.00163	0.00181	CcSEcCtD
Flecainide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00162	0.00181	CcSEcCtD
Flecainide—Jaundice—Doxorubicin—thyroid cancer	0.00162	0.0018	CcSEcCtD
Flecainide—Hypoaesthesia—Epirubicin—thyroid cancer	0.0016	0.00178	CcSEcCtD
Flecainide—Haematuria—Doxorubicin—thyroid cancer	0.00158	0.00176	CcSEcCtD
Flecainide—Visual impairment—Epirubicin—thyroid cancer	0.00155	0.00172	CcSEcCtD
Flecainide—Agranulocytosis—Doxorubicin—thyroid cancer	0.00155	0.00172	CcSEcCtD
Flecainide—Bradycardia—Doxorubicin—thyroid cancer	0.00151	0.00168	CcSEcCtD
Flecainide—Eye disorder—Epirubicin—thyroid cancer	0.0015	0.00167	CcSEcCtD
Flecainide—Tinnitus—Epirubicin—thyroid cancer	0.0015	0.00167	CcSEcCtD
Flecainide—Flushing—Epirubicin—thyroid cancer	0.00149	0.00166	CcSEcCtD
Flecainide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00148	0.00165	CcSEcCtD
Flecainide—Immune system disorder—Epirubicin—thyroid cancer	0.00145	0.00162	CcSEcCtD
Flecainide—Visual impairment—Doxorubicin—thyroid cancer	0.00143	0.00159	CcSEcCtD
Flecainide—Alopecia—Epirubicin—thyroid cancer	0.00142	0.00158	CcSEcCtD
Flecainide—Eye disorder—Doxorubicin—thyroid cancer	0.00139	0.00155	CcSEcCtD
Flecainide—Tinnitus—Doxorubicin—thyroid cancer	0.00139	0.00154	CcSEcCtD
Flecainide—Flushing—Doxorubicin—thyroid cancer	0.00138	0.00154	CcSEcCtD
Flecainide—Flatulence—Epirubicin—thyroid cancer	0.00138	0.00153	CcSEcCtD
Flecainide—Tension—Epirubicin—thyroid cancer	0.00137	0.00153	CcSEcCtD
Flecainide—Dysgeusia—Epirubicin—thyroid cancer	0.00137	0.00152	CcSEcCtD
Flecainide—Nervousness—Epirubicin—thyroid cancer	0.00136	0.00151	CcSEcCtD
Flecainide—Immune system disorder—Doxorubicin—thyroid cancer	0.00134	0.00149	CcSEcCtD
Flecainide—Vision blurred—Epirubicin—thyroid cancer	0.00132	0.00147	CcSEcCtD
Flecainide—Alopecia—Doxorubicin—thyroid cancer	0.00131	0.00146	CcSEcCtD
Flecainide—Ill-defined disorder—Epirubicin—thyroid cancer	0.0013	0.00144	CcSEcCtD
Flecainide—Flatulence—Doxorubicin—thyroid cancer	0.00128	0.00142	CcSEcCtD
Flecainide—Tension—Doxorubicin—thyroid cancer	0.00127	0.00141	CcSEcCtD
Flecainide—Dysgeusia—Doxorubicin—thyroid cancer	0.00127	0.00141	CcSEcCtD
Flecainide—Malaise—Epirubicin—thyroid cancer	0.00126	0.0014	CcSEcCtD
Flecainide—Nervousness—Doxorubicin—thyroid cancer	0.00126	0.0014	CcSEcCtD
Flecainide—Vertigo—Epirubicin—thyroid cancer	0.00126	0.0014	CcSEcCtD
Flecainide—Syncope—Epirubicin—thyroid cancer	0.00126	0.0014	CcSEcCtD
Flecainide—Leukopenia—Epirubicin—thyroid cancer	0.00125	0.00139	CcSEcCtD
Flecainide—Palpitations—Epirubicin—thyroid cancer	0.00124	0.00138	CcSEcCtD
Flecainide—Loss of consciousness—Epirubicin—thyroid cancer	0.00123	0.00137	CcSEcCtD
Flecainide—Cough—Epirubicin—thyroid cancer	0.00122	0.00136	CcSEcCtD
Flecainide—Vision blurred—Doxorubicin—thyroid cancer	0.00122	0.00136	CcSEcCtD
Flecainide—Convulsion—Epirubicin—thyroid cancer	0.00121	0.00135	CcSEcCtD
Flecainide—Hypertension—Epirubicin—thyroid cancer	0.00121	0.00134	CcSEcCtD
Flecainide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.0012	0.00134	CcSEcCtD
Flecainide—Chest pain—Epirubicin—thyroid cancer	0.00119	0.00133	CcSEcCtD
Flecainide—Myalgia—Epirubicin—thyroid cancer	0.00119	0.00133	CcSEcCtD
Flecainide—Arthralgia—Epirubicin—thyroid cancer	0.00119	0.00133	CcSEcCtD
Flecainide—Anxiety—Epirubicin—thyroid cancer	0.00119	0.00132	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00118	0.00132	CcSEcCtD
Flecainide—Discomfort—Epirubicin—thyroid cancer	0.00118	0.00131	CcSEcCtD
Flecainide—Malaise—Doxorubicin—thyroid cancer	0.00117	0.0013	CcSEcCtD
Flecainide—Dry mouth—Epirubicin—thyroid cancer	0.00117	0.0013	CcSEcCtD
Flecainide—Vertigo—Doxorubicin—thyroid cancer	0.00116	0.00129	CcSEcCtD
Flecainide—Syncope—Doxorubicin—thyroid cancer	0.00116	0.00129	CcSEcCtD
Flecainide—Leukopenia—Doxorubicin—thyroid cancer	0.00116	0.00129	CcSEcCtD
Flecainide—Confusional state—Epirubicin—thyroid cancer	0.00115	0.00128	CcSEcCtD
Flecainide—Palpitations—Doxorubicin—thyroid cancer	0.00114	0.00127	CcSEcCtD
Flecainide—Oedema—Epirubicin—thyroid cancer	0.00114	0.00127	CcSEcCtD
Flecainide—Loss of consciousness—Doxorubicin—thyroid cancer	0.00114	0.00127	CcSEcCtD
Flecainide—Cough—Doxorubicin—thyroid cancer	0.00113	0.00126	CcSEcCtD
Flecainide—Shock—Epirubicin—thyroid cancer	0.00112	0.00125	CcSEcCtD
Flecainide—Convulsion—Doxorubicin—thyroid cancer	0.00112	0.00125	CcSEcCtD
Flecainide—Nervous system disorder—Epirubicin—thyroid cancer	0.00112	0.00125	CcSEcCtD
Flecainide—Thrombocytopenia—Epirubicin—thyroid cancer	0.00112	0.00124	CcSEcCtD
Flecainide—Hypertension—Doxorubicin—thyroid cancer	0.00112	0.00124	CcSEcCtD
Flecainide—Tachycardia—Epirubicin—thyroid cancer	0.00112	0.00124	CcSEcCtD
Flecainide—Skin disorder—Epirubicin—thyroid cancer	0.00111	0.00123	CcSEcCtD
Flecainide—Hyperhidrosis—Epirubicin—thyroid cancer	0.0011	0.00123	CcSEcCtD
Flecainide—Chest pain—Doxorubicin—thyroid cancer	0.0011	0.00123	CcSEcCtD
Flecainide—Myalgia—Doxorubicin—thyroid cancer	0.0011	0.00123	CcSEcCtD
Flecainide—Arthralgia—Doxorubicin—thyroid cancer	0.0011	0.00123	CcSEcCtD
Flecainide—Anxiety—Doxorubicin—thyroid cancer	0.0011	0.00122	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0011	0.00122	CcSEcCtD
Flecainide—Discomfort—Doxorubicin—thyroid cancer	0.00109	0.00121	CcSEcCtD
Flecainide—Anorexia—Epirubicin—thyroid cancer	0.00109	0.00121	CcSEcCtD
Flecainide—Dry mouth—Doxorubicin—thyroid cancer	0.00108	0.0012	CcSEcCtD
Flecainide—Hypotension—Epirubicin—thyroid cancer	0.00107	0.00119	CcSEcCtD
Flecainide—Confusional state—Doxorubicin—thyroid cancer	0.00107	0.00119	CcSEcCtD
Flecainide—Oedema—Doxorubicin—thyroid cancer	0.00106	0.00118	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00104	0.00116	CcSEcCtD
Flecainide—Shock—Doxorubicin—thyroid cancer	0.00104	0.00116	CcSEcCtD
Flecainide—Nervous system disorder—Doxorubicin—thyroid cancer	0.00104	0.00115	CcSEcCtD
Flecainide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00104	0.00115	CcSEcCtD
Flecainide—Insomnia—Epirubicin—thyroid cancer	0.00103	0.00115	CcSEcCtD
Flecainide—Tachycardia—Doxorubicin—thyroid cancer	0.00103	0.00115	CcSEcCtD
Flecainide—Skin disorder—Doxorubicin—thyroid cancer	0.00103	0.00114	CcSEcCtD
Flecainide—Paraesthesia—Epirubicin—thyroid cancer	0.00103	0.00114	CcSEcCtD
Flecainide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00102	0.00114	CcSEcCtD
Flecainide—Dyspnoea—Epirubicin—thyroid cancer	0.00102	0.00113	CcSEcCtD
Flecainide—Somnolence—Epirubicin—thyroid cancer	0.00102	0.00113	CcSEcCtD
Flecainide—Anorexia—Doxorubicin—thyroid cancer	0.00101	0.00112	CcSEcCtD
Flecainide—Dyspepsia—Epirubicin—thyroid cancer	0.00101	0.00112	CcSEcCtD
Flecainide—Decreased appetite—Epirubicin—thyroid cancer	0.000993	0.0011	CcSEcCtD
Flecainide—Hypotension—Doxorubicin—thyroid cancer	0.000988	0.0011	CcSEcCtD
Flecainide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000986	0.0011	CcSEcCtD
Flecainide—Fatigue—Epirubicin—thyroid cancer	0.000985	0.0011	CcSEcCtD
Flecainide—Pain—Epirubicin—thyroid cancer	0.000977	0.00109	CcSEcCtD
Flecainide—Constipation—Epirubicin—thyroid cancer	0.000977	0.00109	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000963	0.00107	CcSEcCtD
Flecainide—Insomnia—Doxorubicin—thyroid cancer	0.000956	0.00106	CcSEcCtD
Flecainide—Paraesthesia—Doxorubicin—thyroid cancer	0.000949	0.00106	CcSEcCtD
Flecainide—Dyspnoea—Doxorubicin—thyroid cancer	0.000943	0.00105	CcSEcCtD
Flecainide—Feeling abnormal—Epirubicin—thyroid cancer	0.000942	0.00105	CcSEcCtD
Flecainide—Somnolence—Doxorubicin—thyroid cancer	0.00094	0.00105	CcSEcCtD
Flecainide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000934	0.00104	CcSEcCtD
Flecainide—Dyspepsia—Doxorubicin—thyroid cancer	0.000931	0.00104	CcSEcCtD
Flecainide—Decreased appetite—Doxorubicin—thyroid cancer	0.000919	0.00102	CcSEcCtD
Flecainide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000913	0.00102	CcSEcCtD
Flecainide—Fatigue—Doxorubicin—thyroid cancer	0.000912	0.00101	CcSEcCtD
Flecainide—Urticaria—Epirubicin—thyroid cancer	0.000908	0.00101	CcSEcCtD
Flecainide—Constipation—Doxorubicin—thyroid cancer	0.000904	0.00101	CcSEcCtD
Flecainide—Pain—Doxorubicin—thyroid cancer	0.000904	0.00101	CcSEcCtD
Flecainide—Abdominal pain—Epirubicin—thyroid cancer	0.000903	0.001	CcSEcCtD
Flecainide—Body temperature increased—Epirubicin—thyroid cancer	0.000903	0.001	CcSEcCtD
Flecainide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000871	0.000969	CcSEcCtD
Flecainide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000865	0.000962	CcSEcCtD
Flecainide—Urticaria—Doxorubicin—thyroid cancer	0.00084	0.000934	CcSEcCtD
Flecainide—Body temperature increased—Doxorubicin—thyroid cancer	0.000836	0.00093	CcSEcCtD
Flecainide—Abdominal pain—Doxorubicin—thyroid cancer	0.000836	0.00093	CcSEcCtD
Flecainide—Asthenia—Epirubicin—thyroid cancer	0.00082	0.000912	CcSEcCtD
Flecainide—Pruritus—Epirubicin—thyroid cancer	0.000808	0.000899	CcSEcCtD
Flecainide—Diarrhoea—Epirubicin—thyroid cancer	0.000782	0.000869	CcSEcCtD
Flecainide—Asthenia—Doxorubicin—thyroid cancer	0.000759	0.000844	CcSEcCtD
Flecainide—Dizziness—Epirubicin—thyroid cancer	0.000756	0.00084	CcSEcCtD
Flecainide—Pruritus—Doxorubicin—thyroid cancer	0.000748	0.000832	CcSEcCtD
Flecainide—Vomiting—Epirubicin—thyroid cancer	0.000727	0.000808	CcSEcCtD
Flecainide—Diarrhoea—Doxorubicin—thyroid cancer	0.000723	0.000805	CcSEcCtD
Flecainide—Rash—Epirubicin—thyroid cancer	0.00072	0.000801	CcSEcCtD
Flecainide—Dermatitis—Epirubicin—thyroid cancer	0.00072	0.000801	CcSEcCtD
Flecainide—Headache—Epirubicin—thyroid cancer	0.000716	0.000796	CcSEcCtD
Flecainide—Dizziness—Doxorubicin—thyroid cancer	0.000699	0.000778	CcSEcCtD
Flecainide—Nausea—Epirubicin—thyroid cancer	0.000679	0.000755	CcSEcCtD
Flecainide—Vomiting—Doxorubicin—thyroid cancer	0.000672	0.000748	CcSEcCtD
Flecainide—Rash—Doxorubicin—thyroid cancer	0.000667	0.000741	CcSEcCtD
Flecainide—Dermatitis—Doxorubicin—thyroid cancer	0.000666	0.000741	CcSEcCtD
Flecainide—Headache—Doxorubicin—thyroid cancer	0.000662	0.000737	CcSEcCtD
Flecainide—Nausea—Doxorubicin—thyroid cancer	0.000628	0.000698	CcSEcCtD
